Top Industry Leaders in the Seropositive Rheumatoid Arthritis Drug Market
Latest Seropositive Rheumatoid Arthritis Drug Companies Updates:
AbbVie receives FDA approval for Rinvoq® (upadacitinib) for the treatment of active adult psoriatic arthritis, expanding its reach beyond rheumatoid arthritis: This approval strengthens
AbbVie's position in the autoimmune disease treatment landscape.
Pfizer announces positive Phase 3 trial results for Xeljanz® (tofacitinib) in combination with methotrexate for the treatment of active psoriatic arthritis: These results further demonstrate the potential of Xeljanz as an effective treatment option for this condition.
Roche launches Tecentriq® (atezolizumab) in combination with methotrexate for the treatment of adult patients with moderate-to-severe rheumatoid arthritis who have had an
inadequate response to one or more DMARDs: This represents a significant step forward in immunotherapy options for rheumatoid arthritis.
List of Seropositive Rheumatoid Arthritis Drug Key companies in the market:
- Abbott Laboratories (U.S.)
- Johnson & Johnson Limited (U.S.)
- Novartis AG (Switzerland)
- Pfizer, Inc. (U.S.)
- Eli Lilly and Company (U.S.)
- AbbVie Inc. (U.S.)
- Bristol-Myers Squibb Company (U.S.)
- F. Hoffmann-La Roche Ltd. (Switzerland)
